ECMO

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, SAFE, Growth, HOPE, CE, Patient, PMR, ACTION, UKCA, Hydrocephalus, ECMO, News, MDR, Pediatrics, Malnutrition, Nursing care plan, Marketing, FDA, Video game

Revenues for the fourth quarter of 2023 were $2.69 million, up 89%, compared to $1.42 million in the fourth quarter of 2022.

Key Points: 
  • Revenues for the fourth quarter of 2023 were $2.69 million, up 89%, compared to $1.42 million in the fourth quarter of 2022.
  • Gross margin for the fourth quarter of 2023 was $1.03 million, compared to $0.30 million in the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter of 2023 were $5.96 million, compared to $5.22 million in the fourth quarter of 2022.
  • Sales, marketing, general, and administrative expenses for the fourth quarter of 2023 were $6.70 million, compared to $8.71 million in the fourth quarter of 2022.

Em-tec Announces Release of SonoTT aQuila System

Retrieved on: 
Wednesday, March 27, 2024
Anomaly, Product management, Finning, ECMO, PSG, Blood, HLM, Extracorporeal membrane oxygenation, Yolo Bypass, Documentation, Safety, Medical device

The SonoTT aQuila Flow Measurement System is designed to advance the safety and quality of flow-measurement applications during a variety of medical treatments, such as extracorporeal membrane oxygenation (ECMO), the use of a heart-lung machine (HLM), apheresis, (hemo)dialysis, and distal perfusion.

Key Points: 
  • The SonoTT aQuila Flow Measurement System is designed to advance the safety and quality of flow-measurement applications during a variety of medical treatments, such as extracorporeal membrane oxygenation (ECMO), the use of a heart-lung machine (HLM), apheresis, (hemo)dialysis, and distal perfusion.
  • "We are excited to launch the new SonoTT aQuila System, which represents the next-generation technology that allows us to better serve our existing and new customers and open up strategically important markets," said Christian Steer, Director of Product Management at Em-tec.
  • Stand-alone sensor technology, such as that offered by Em-tec's new SonoTT aQuila System, can be flexibly used for the independent measurement and display of blood flow values, resulting in enhanced safety and quality in a wide variety of treatment methods in which blood flow monitoring is vital.
  • The innovative SonoTT aQuila System was developed at the Finning site in Germany.

Volition appoints Dr Andrew Retter as Chief Medical Officer

Retrieved on: 
Tuesday, March 19, 2024
NHS foundation trust, Thrombosis, Sepsis, Guy, Disease, Neutrophil extracellular traps, Consultant, Patient, Research, Intensive care medicine, Respiratory failure, ECMO, NETS, Cancer, Heart, Nursing care plan, Clinical governance, Nursing

HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.

Key Points: 
  • HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.
  • Dr Retter will provide medical leadership at Volition and ensure the company's scientific and clinical efforts are aligned with patient needs.
  • Cameron Reynolds, President and Group Chief Executive Officer at Volition, said: "We are delighted to welcome Andrew to Volition.
  • As Chief Medical Officer he will be vital to our success – ensuring the needs of the patient are placed at the heart of our research, development and commercialization activities."

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

Retrieved on: 
Thursday, January 25, 2024
ANN, Death, Mortality, Patient, The Lancet, Intubation, Hospital, Intensive care medicine, FCCP, COVID-19 deaths, Internal medicine, Survival, Medicine, ECMO, Critical care, Food, Commitment, Disease, COVID-19, FDA, Therapy, IMV, Extracorporeal membrane oxygenation, Emergency Use Authorization, Physician, Pharmaceutical industry

InflaRx is determined to support broader access to GOHIBIC for eligible patients.

Key Points: 
  • InflaRx is determined to support broader access to GOHIBIC for eligible patients.
  • ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has launched The InflaRx Commitment Program (Commitment Program).
  • With today´s announcement, we are demonstrating our strong commitment to help make GOHIBIC available for the most affected COVID-19 patients as a potential life-saving therapy.
  • For detailed information about the Commitment Program and to file a claim, please visit this link: The InflaRx Commitment Program .

Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study

Retrieved on: 
Tuesday, January 9, 2024
General Health, Health, Surgery, Organ transplantation, Medical University of Vienna, Patient, Risk, CTS, Medical school, Survival, Freezing, Lung transplantation, ECMO, PGD, Physician, Dentistry

The use of extended criteria donor organs can increase the availability of life-saving transplantable organs, proving to be a valuable solution to those on the waitlist in need of an organ transplant.

Key Points: 
  • The use of extended criteria donor organs can increase the availability of life-saving transplantable organs, proving to be a valuable solution to those on the waitlist in need of an organ transplant.
  • The Paragonix SherpaPak CTS is a static hypothermic preservation device intended to protect the donor heart during transit, standardizing the internal environment to maintain a recommended thermal range above freezing, unlike traditionally used ice-cold storage.
  • Published in the esteemed Journal of Heart and Lung Transplantation, this study compared the effectiveness of ice-cold storage against the Paragonix SherpaPak CTS, assessing the post-transplant outcomes of recipients who received an extended criteria donor heart.
  • “The study finds the Paragonix SherpaPak Cardiac Transport System provides a clinically effective solution to safely increase donor heart utilization.

Human medicines European public assessment report (EPAR): Veklury, remdesivir, Date of authorisation: 03/07/2020, Revision: 23, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
RNA, Medical Subject Headings, Marketing, Liver, INN, Risk, Adolescence, Pneumonia, Extracorporeal membrane oxygenation, COVID 19, International, Mortality, ECMO, Nausea, Language, Ventilation, COVID, COVID-19, European Medicines Agency, SARS-CoV-2, Risk management, Select, Cell, Patient, Safety, IIA, Viral, Medical device

Human medicines European public assessment report (EPAR): Veklury, remdesivir, Date of authorisation: 03/07/2020, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Veklury, remdesivir, Date of authorisation: 03/07/2020, Revision: 23, Status: Authorised

Extracorporeal Membrane Oxygenation Machines Market to grow by USD 243.6 million from 2022 to 2027 | North America to account for 37% of market growth- Technavio

Retrieved on: 
Friday, November 24, 2023
Abbott Laboratories, ECMO, LivaNova, ROW, Laboratory, Research, Otoscope, USD, Medtronic, PMP, Software, Abiomed, Fresenius Medical Care, Growth, Getinge Group, Free, Retail, Sewage treatment, Speciality chemicals

NEW YORK, Nov. 24, 2023 /PRNewswire/ --The extracorporeal membrane oxygenation machines market size is expected to grow by USD 243.6 million from 2022 to 2027.

Key Points: 
  • NEW YORK, Nov. 24, 2023 /PRNewswire/ --The extracorporeal membrane oxygenation machines market size is expected to grow by USD 243.6 million from 2022 to 2027.
  • Extracorporeal Membrane Oxygenation Machines Market: Segmentation Analysis
    The market share growth by the veno-venous segment will be significant during the forecast period.
  • Detailed information on factors that will drive the growth of the extracorporeal membrane oxygenation machines market between 2022 and 2027.
  • Growth of the extracorporeal membrane oxygenation machines market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of extracorporeal membrane oxygenation machines market companies.

Understanding Survival Factors in Critically Ill Patients on Extracorporeal Membrane Oxygenation

Retrieved on: 
Friday, November 17, 2023
Hospice and palliative medicine, Extracorporeal membrane oxygenation, ECMO, Intensive care unit, Prevalence, Chung-Ang University, Ageing, Risk, ICU, Mortality, Patient, Intensive care medicine, Heart, COVID-19, MAP, Critical care nursing, Survival, Death, Survivor, Professor, Intensive word form, Collaboration, Medical device, Nursing, Pharmaceutical industry

SEOUL, Nov. 17, 2023 /PRNewswire/ -- Extracorporeal membrane oxygenation (ECMO), a widely used life support modality, is associated with a high in-hospital mortality rate. Now, researchers from Chung-Ang University, Korea have assessed the prevalence of ECMO-associated deaths and identified the related risk factors. These findings aim to enhance the management of patients requiring ECMO.

Key Points: 
  • SEOUL, Nov. 17, 2023 /PRNewswire/ -- Extracorporeal membrane oxygenation (ECMO), a widely used life support modality, is associated with a high in-hospital mortality rate.
  • Extracorporeal membrane oxygenation (ECMO) is a vital life support procedure that provides cardiac and respiratory support to critically ill patients.
  • Identifying risk factors for in-hospital mortality and developing standardized nursing practice guidelines for ECMO management may improve survival rates.
  • Title of original paper: Factors associated with 30-day in-hospital mortality in critically ill adult patients receiving extracorporeal membrane oxygenation: A retrospective cohort study